Efficacy and Safety Study of Vicagrel in Patients With Acute Coronary Syndrome (ACS) Undergoing P… (NCT06577519) | Clinical Trial Compass
RecruitingPhase 3
Efficacy and Safety Study of Vicagrel in Patients With Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)
China1,000 participantsStarted 2024-09-06
Plain-language summary
This is a multi-center, randomized, double-blind, double-dummy, parallel-controled, phase III trial, aiming to evaluate the effectiveness and safety of long-term continuous administration of Vicagrel capsules in ACS patients undergoing PCI.
Who can participate
Age range18 Years – 80 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patients between 18 and 80 years old, with no gender restrictions.
* Patients diagnosed with ACS and scheduled for PCI, including STEMI and NSTE-ACS (UA/NSTEMI).
* Voluntarily sign the ICF and be able to follow the visit arrangements specified in the protocol during the trial period.
Exclusion Criteria:
* Expected survival time\<12 months;
* Severe liver dysfunction (non heart disease induced ALT or AST\>3x ULN) and cirrhosis;
* Pregnant or lactating women, or participants and their partners who plan to become pregnant during the trial period;
* The researchers determined that other reasons were not suitable for participants in this experiment.